Andrew Liu
Concepts (402)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 85 | 2022 | 2257 | 7.900 |
Why?
| Urban Population | 17 | 2022 | 442 | 3.330 |
Why?
| Hypersensitivity | 16 | 2023 | 277 | 3.320 |
Why?
| Anti-Asthmatic Agents | 15 | 2020 | 377 | 1.730 |
Why?
| Environmental Exposure | 8 | 2018 | 479 | 1.630 |
Why?
| Severity of Illness Index | 15 | 2021 | 2783 | 1.270 |
Why?
| Child | 71 | 2022 | 20963 | 1.080 |
Why?
| Allergens | 17 | 2022 | 463 | 1.060 |
Why?
| Virus Diseases | 4 | 2022 | 211 | 1.030 |
Why?
| Nasal Mucosa | 6 | 2019 | 108 | 1.010 |
Why?
| Endotoxins | 4 | 2013 | 222 | 0.880 |
Why?
| Immunoglobulin E | 21 | 2020 | 354 | 0.870 |
Why?
| Rhinitis | 5 | 2018 | 152 | 0.840 |
Why?
| Poverty | 7 | 2016 | 493 | 0.820 |
Why?
| Omalizumab | 9 | 2020 | 59 | 0.800 |
Why?
| Oscillometry | 3 | 2021 | 37 | 0.790 |
Why?
| Air Pollution, Indoor | 2 | 2021 | 139 | 0.760 |
Why?
| Phenotype | 7 | 2018 | 3063 | 0.750 |
Why?
| Child, Preschool | 33 | 2021 | 10565 | 0.750 |
Why?
| Airway Resistance | 2 | 2020 | 38 | 0.750 |
Why?
| Respiratory Sounds | 8 | 2022 | 121 | 0.700 |
Why?
| Hygiene | 4 | 2015 | 31 | 0.670 |
Why?
| Biological Products | 1 | 2023 | 202 | 0.650 |
Why?
| Humans | 107 | 2023 | 129706 | 0.640 |
Why?
| Respiratory Function Tests | 8 | 2015 | 594 | 0.640 |
Why?
| Inhalation Exposure | 1 | 2013 | 109 | 0.630 |
Why?
| Food Hypersensitivity | 3 | 2014 | 286 | 0.600 |
Why?
| Adolescent | 40 | 2022 | 20355 | 0.580 |
Why?
| Respiratory Syncytial Virus, Human | 1 | 2018 | 68 | 0.570 |
Why?
| Microbiota | 4 | 2022 | 727 | 0.560 |
Why?
| Rhinovirus | 6 | 2023 | 56 | 0.560 |
Why?
| Disease Progression | 10 | 2021 | 2612 | 0.550 |
Why?
| Adrenal Cortex Hormones | 7 | 2018 | 526 | 0.530 |
Why?
| Hygiene Hypothesis | 1 | 2015 | 1 | 0.510 |
Why?
| Air Pollutants | 1 | 2013 | 316 | 0.500 |
Why?
| Biological Therapy | 1 | 2015 | 30 | 0.490 |
Why?
| Prevalence | 10 | 2018 | 2557 | 0.450 |
Why?
| Male | 60 | 2022 | 63544 | 0.450 |
Why?
| Dust | 5 | 2021 | 100 | 0.450 |
Why?
| Nitrogen Dioxide | 1 | 2013 | 33 | 0.440 |
Why?
| Female | 61 | 2022 | 68562 | 0.430 |
Why?
| Bronchodilator Agents | 6 | 2021 | 253 | 0.410 |
Why?
| Cockroaches | 5 | 2021 | 23 | 0.410 |
Why?
| Spirometry | 6 | 2021 | 251 | 0.410 |
Why?
| Models, Theoretical | 1 | 2016 | 551 | 0.410 |
Why?
| Egg Hypersensitivity | 4 | 2016 | 47 | 0.410 |
Why?
| Peanut Hypersensitivity | 5 | 2015 | 208 | 0.400 |
Why?
| Leukocytes, Mononuclear | 8 | 2021 | 543 | 0.390 |
Why?
| Desensitization, Immunologic | 4 | 2016 | 134 | 0.380 |
Why?
| Epigenesis, Genetic | 6 | 2018 | 614 | 0.380 |
Why?
| Risk Factors | 15 | 2022 | 9832 | 0.370 |
Why?
| Nicotine | 1 | 2013 | 303 | 0.360 |
Why?
| Disease Management | 4 | 2016 | 596 | 0.350 |
Why?
| Stress, Psychological | 1 | 2018 | 1051 | 0.330 |
Why?
| Hypersensitivity, Immediate | 3 | 2012 | 48 | 0.330 |
Why?
| Infant | 18 | 2021 | 9097 | 0.320 |
Why?
| Picornaviridae Infections | 1 | 2023 | 45 | 0.310 |
Why?
| Receptors, Pattern Recognition | 1 | 2008 | 10 | 0.310 |
Why?
| Arachis | 5 | 2015 | 156 | 0.310 |
Why?
| Primary Health Care | 3 | 2021 | 1668 | 0.310 |
Why?
| Bacterial Infections | 2 | 2008 | 240 | 0.310 |
Why?
| Maxillary Sinus | 2 | 2009 | 11 | 0.310 |
Why?
| Environmental Monitoring | 2 | 2013 | 326 | 0.300 |
Why?
| Urban Health | 4 | 2013 | 79 | 0.290 |
Why?
| Emergency Service, Hospital | 3 | 2021 | 2044 | 0.290 |
Why?
| Precision Medicine | 2 | 2021 | 385 | 0.280 |
Why?
| Environmental Microbiology | 2 | 2007 | 46 | 0.280 |
Why?
| Prospective Studies | 7 | 2022 | 7131 | 0.280 |
Why?
| DNA Methylation | 5 | 2018 | 601 | 0.270 |
Why?
| Fluticasone | 6 | 2018 | 90 | 0.260 |
Why?
| Sinusitis | 1 | 2009 | 204 | 0.260 |
Why?
| Immune System | 1 | 2007 | 177 | 0.260 |
Why?
| Epithelial Cells | 2 | 2023 | 1060 | 0.260 |
Why?
| Practice Guidelines as Topic | 7 | 2018 | 1529 | 0.260 |
Why?
| Antibodies, Anti-Idiotypic | 3 | 2013 | 56 | 0.260 |
Why?
| Biomarkers | 6 | 2022 | 3893 | 0.260 |
Why?
| Dermatitis, Atopic | 5 | 2014 | 335 | 0.250 |
Why?
| Transcriptome | 4 | 2022 | 872 | 0.250 |
Why?
| Baltimore | 2 | 2016 | 46 | 0.240 |
Why?
| Antibodies, Monoclonal | 3 | 2020 | 1360 | 0.240 |
Why?
| Adrenergic beta-Agonists | 2 | 2009 | 132 | 0.240 |
Why?
| Pulmonary Surfactant-Associated Protein A | | | 34 | NaN |
Why?
| United States | 12 | 2022 | 14078 | 0.230 |
Why?
| Recurrence | 2 | 2018 | 1016 | 0.230 |
Why?
| Maxillary Sinusitis | 1 | 2004 | 7 | 0.230 |
Why?
| Respiratory Tract Infections | 2 | 2019 | 373 | 0.220 |
Why?
| Medicaid | 1 | 2006 | 447 | 0.210 |
Why?
| Treatment Outcome | 13 | 2017 | 10299 | 0.210 |
Why?
| Cities | 2 | 2018 | 101 | 0.210 |
Why?
| Host-Pathogen Interactions | 2 | 2017 | 349 | 0.210 |
Why?
| Maternal Exposure | 2 | 2018 | 173 | 0.210 |
Why?
| Biological Factors | 1 | 2023 | 37 | 0.210 |
Why?
| Skin Tests | 7 | 2014 | 126 | 0.200 |
Why?
| Immunity, Innate | 1 | 2008 | 806 | 0.200 |
Why?
| Quality of Life | 2 | 2021 | 2712 | 0.200 |
Why?
| Pulmonary Eosinophilia | 1 | 2022 | 28 | 0.200 |
Why?
| Eosinophils | 3 | 2019 | 324 | 0.200 |
Why?
| Rhinitis, Allergic, Perennial | 2 | 2016 | 24 | 0.200 |
Why?
| Self Care | 1 | 2005 | 374 | 0.200 |
Why?
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 751 | 0.200 |
Why?
| Pulmonary Surfactants | 1 | 2023 | 108 | 0.200 |
Why?
| Pediatrics | 1 | 2010 | 1071 | 0.190 |
Why?
| DNA, Bacterial | 1 | 2003 | 326 | 0.190 |
Why?
| Forced Expiratory Volume | 5 | 2017 | 508 | 0.190 |
Why?
| Administration, Inhalation | 6 | 2016 | 676 | 0.190 |
Why?
| Early Growth Response Protein 1 | 1 | 2021 | 27 | 0.190 |
Why?
| CpG Islands | 2 | 2018 | 151 | 0.190 |
Why?
| Milk Hypersensitivity | 2 | 2012 | 25 | 0.180 |
Why?
| Respiratory Syncytial Virus Infections | 2 | 2018 | 118 | 0.180 |
Why?
| Double-Blind Method | 10 | 2016 | 1871 | 0.180 |
Why?
| Gene Expression Profiling | 4 | 2017 | 1696 | 0.180 |
Why?
| Immune Tolerance | 2 | 2014 | 348 | 0.180 |
Why?
| Surveys and Questionnaires | 4 | 2018 | 5396 | 0.180 |
Why?
| Housing | 4 | 2021 | 132 | 0.180 |
Why?
| Mucin 5AC | 1 | 2021 | 69 | 0.180 |
Why?
| Tobacco Smoke Pollution | 3 | 2016 | 233 | 0.180 |
Why?
| Quantitative Trait Loci | 3 | 2021 | 355 | 0.180 |
Why?
| Enterovirus Infections | 1 | 2023 | 171 | 0.170 |
Why?
| Anti-Allergic Agents | 2 | 2018 | 50 | 0.170 |
Why?
| Cross-Sectional Studies | 7 | 2020 | 5050 | 0.170 |
Why?
| Nitric Oxide | 4 | 2015 | 894 | 0.160 |
Why?
| Bronchial Hyperreactivity | 3 | 2012 | 105 | 0.160 |
Why?
| Intellectual Disability | 1 | 2021 | 153 | 0.160 |
Why?
| Gene Expression Regulation | 6 | 2021 | 2522 | 0.160 |
Why?
| Autoimmune Diseases | 1 | 2003 | 422 | 0.160 |
Why?
| ERG1 Potassium Channel | 1 | 2018 | 4 | 0.160 |
Why?
| Adult | 20 | 2022 | 35596 | 0.160 |
Why?
| Interleukin-5 Receptor alpha Subunit | 1 | 2018 | 6 | 0.160 |
Why?
| Androstadienes | 3 | 2009 | 107 | 0.160 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2021 | 1379 | 0.160 |
Why?
| Decision Making, Computer-Assisted | 1 | 2018 | 18 | 0.160 |
Why?
| Genotype | 2 | 2021 | 1836 | 0.150 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2018 | 55 | 0.150 |
Why?
| Respiratory System | 1 | 2019 | 153 | 0.150 |
Why?
| Eczema | 2 | 2010 | 83 | 0.140 |
Why?
| Nutrition Surveys | 4 | 2014 | 259 | 0.140 |
Why?
| Interleukin-6 | 2 | 2020 | 715 | 0.140 |
Why?
| Acute Disease | 1 | 2020 | 984 | 0.140 |
Why?
| Age of Onset | 2 | 2016 | 494 | 0.140 |
Why?
| Seasons | 5 | 2022 | 508 | 0.140 |
Why?
| Lipopolysaccharides | 3 | 2008 | 880 | 0.140 |
Why?
| RNA Virus Infections | 1 | 2017 | 13 | 0.140 |
Why?
| Infant, Newborn | 4 | 2018 | 5752 | 0.140 |
Why?
| Gene Regulatory Networks | 1 | 2019 | 278 | 0.140 |
Why?
| RNA, Ribosomal, 16S | 1 | 2019 | 521 | 0.140 |
Why?
| Fluticasone-Salmeterol Drug Combination | 1 | 2016 | 12 | 0.130 |
Why?
| Age Factors | 4 | 2006 | 3145 | 0.130 |
Why?
| Guideline Adherence | 1 | 2021 | 531 | 0.130 |
Why?
| RNA Viruses | 1 | 2017 | 33 | 0.130 |
Why?
| Epidemiologic Studies | 1 | 2016 | 66 | 0.130 |
Why?
| Basophils | 3 | 2015 | 71 | 0.130 |
Why?
| Follow-Up Studies | 6 | 2018 | 4939 | 0.130 |
Why?
| Feasibility Studies | 1 | 2020 | 876 | 0.130 |
Why?
| Plasma Cells | 2 | 2009 | 65 | 0.130 |
Why?
| Medical History Taking | 1 | 2016 | 122 | 0.130 |
Why?
| Antiviral Agents | 2 | 2023 | 709 | 0.130 |
Why?
| Immunization | 2 | 2016 | 423 | 0.130 |
Why?
| Lung | 3 | 2023 | 3928 | 0.130 |
Why?
| Immune System Diseases | 1 | 2015 | 33 | 0.120 |
Why?
| Socioeconomic Factors | 3 | 2016 | 1212 | 0.120 |
Why?
| Air Pollution | 1 | 2018 | 223 | 0.120 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2021 | 2071 | 0.120 |
Why?
| Sublingual Immunotherapy | 1 | 2015 | 8 | 0.120 |
Why?
| Cluster Analysis | 1 | 2016 | 482 | 0.120 |
Why?
| Longitudinal Studies | 3 | 2019 | 2670 | 0.120 |
Why?
| Down Syndrome | 1 | 2021 | 455 | 0.120 |
Why?
| Genome-Wide Association Study | 3 | 2018 | 1334 | 0.120 |
Why?
| Neoplasm Proteins | 1 | 2018 | 429 | 0.120 |
Why?
| Rural Health | 2 | 2006 | 71 | 0.120 |
Why?
| Metabolic Diseases | 1 | 2015 | 106 | 0.110 |
Why?
| Schools | 1 | 2018 | 446 | 0.110 |
Why?
| Antigens, Plant | 1 | 2014 | 51 | 0.110 |
Why?
| Young Adult | 10 | 2018 | 12363 | 0.110 |
Why?
| Specimen Handling | 1 | 2015 | 164 | 0.110 |
Why?
| Dendritic Cells | 1 | 2017 | 479 | 0.110 |
Why?
| Infant, Premature | 1 | 2018 | 541 | 0.110 |
Why?
| Parents | 2 | 2022 | 1311 | 0.110 |
Why?
| Animals | 10 | 2021 | 34733 | 0.110 |
Why?
| Respiratory Hypersensitivity | 1 | 2014 | 64 | 0.110 |
Why?
| Physician-Patient Relations | 1 | 2018 | 537 | 0.110 |
Why?
| Gene Expression | 1 | 2018 | 1477 | 0.110 |
Why?
| Telemedicine | 1 | 2022 | 792 | 0.110 |
Why?
| Leukotriene E4 | 2 | 2012 | 26 | 0.110 |
Why?
| Combined Modality Therapy | 1 | 2016 | 1213 | 0.110 |
Why?
| Research | 1 | 2016 | 416 | 0.100 |
Why?
| Genetic Predisposition to Disease | 2 | 2021 | 2272 | 0.100 |
Why?
| Neutrophils | 2 | 2009 | 1205 | 0.100 |
Why?
| Prognosis | 4 | 2017 | 3801 | 0.100 |
Why?
| Biopsy | 2 | 2009 | 1098 | 0.100 |
Why?
| Bronchiolitis | 1 | 2004 | 92 | 0.100 |
Why?
| Hospitalization | 2 | 2021 | 2091 | 0.100 |
Why?
| Indians, North American | 1 | 2018 | 615 | 0.100 |
Why?
| Cohort Studies | 4 | 2018 | 5410 | 0.100 |
Why?
| Homeostasis | 1 | 2015 | 604 | 0.100 |
Why?
| Albuterol | 3 | 2012 | 106 | 0.100 |
Why?
| Adaptive Clinical Trials as Topic | 2 | 2021 | 20 | 0.090 |
Why?
| Membrane Proteins | 1 | 2018 | 1108 | 0.090 |
Why?
| Decision Making | 1 | 2018 | 842 | 0.090 |
Why?
| Obesity | 2 | 2018 | 2851 | 0.090 |
Why?
| Influenza, Human | 1 | 2017 | 610 | 0.090 |
Why?
| Predictive Value of Tests | 3 | 2017 | 1981 | 0.090 |
Why?
| Vitamin D Deficiency | 1 | 2013 | 179 | 0.090 |
Why?
| Time Factors | 3 | 2016 | 6593 | 0.090 |
Why?
| Case-Control Studies | 3 | 2019 | 3363 | 0.090 |
Why?
| Rhinitis, Allergic, Seasonal | 1 | 2010 | 33 | 0.090 |
Why?
| Chronic Disease | 2 | 2009 | 1721 | 0.090 |
Why?
| Comorbidity | 2 | 2015 | 1545 | 0.090 |
Why?
| Nedocromil | 1 | 2010 | 32 | 0.080 |
Why?
| Genomics | 1 | 2015 | 716 | 0.080 |
Why?
| Logistic Models | 3 | 2010 | 1980 | 0.080 |
Why?
| Physicians | 1 | 2018 | 852 | 0.080 |
Why?
| Models, Statistical | 1 | 2013 | 632 | 0.080 |
Why?
| Budesonide | 1 | 2010 | 90 | 0.080 |
Why?
| Vitamin D | 1 | 2013 | 384 | 0.080 |
Why?
| Hexosaminidases | 1 | 2009 | 18 | 0.080 |
Why?
| Health Personnel | 1 | 2015 | 645 | 0.080 |
Why?
| Immunoenzyme Techniques | 1 | 2009 | 210 | 0.080 |
Why?
| Food | 1 | 2010 | 170 | 0.080 |
Why?
| Immunoglobulin G | 4 | 2014 | 842 | 0.080 |
Why?
| Curriculum | 1 | 2015 | 933 | 0.080 |
Why?
| RNA | 1 | 2015 | 877 | 0.080 |
Why?
| Staining and Labeling | 1 | 2009 | 142 | 0.080 |
Why?
| Peroxidase | 1 | 2009 | 183 | 0.080 |
Why?
| Natural Killer T-Cells | 1 | 2009 | 64 | 0.080 |
Why?
| Polysaccharides, Bacterial | 1 | 2008 | 68 | 0.070 |
Why?
| Exhalation | 3 | 2015 | 39 | 0.070 |
Why?
| DNA | 1 | 2015 | 1406 | 0.070 |
Why?
| Health Services Accessibility | 1 | 2015 | 908 | 0.070 |
Why?
| Glucocorticoids | 2 | 2011 | 573 | 0.070 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2009 | 484 | 0.070 |
Why?
| Adrenergic beta-2 Receptor Agonists | 2 | 2018 | 34 | 0.070 |
Why?
| Prednisone | 1 | 2008 | 241 | 0.070 |
Why?
| Macrophage Activation | 1 | 2008 | 178 | 0.070 |
Why?
| Gene Frequency | 2 | 2021 | 503 | 0.070 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 985 | 0.070 |
Why?
| Community Health Nursing | 1 | 2007 | 61 | 0.070 |
Why?
| Infant Care | 1 | 2007 | 46 | 0.070 |
Why?
| Tandem Mass Spectrometry | 1 | 2009 | 441 | 0.070 |
Why?
| Sequence Analysis, RNA | 2 | 2021 | 423 | 0.070 |
Why?
| C-Reactive Protein | 1 | 2009 | 394 | 0.070 |
Why?
| Manure | 1 | 2006 | 7 | 0.070 |
Why?
| Antigens, CD | 1 | 2009 | 479 | 0.070 |
Why?
| Patient Education as Topic | 1 | 2011 | 745 | 0.060 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2006 | 91 | 0.060 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2018 | 1208 | 0.060 |
Why?
| India | 1 | 2006 | 171 | 0.060 |
Why?
| Risk Assessment | 2 | 2006 | 3297 | 0.060 |
Why?
| Electronics, Medical | 1 | 2005 | 7 | 0.060 |
Why?
| Maximum Tolerated Dose | 1 | 2006 | 195 | 0.060 |
Why?
| Biomedical Research | 1 | 2012 | 656 | 0.060 |
Why?
| Bronchial Provocation Tests | 1 | 2005 | 50 | 0.060 |
Why?
| Environment | 1 | 2007 | 348 | 0.060 |
Why?
| Interferon-alpha | 2 | 2017 | 191 | 0.060 |
Why?
| Patient Compliance | 1 | 2009 | 566 | 0.060 |
Why?
| Research Design | 2 | 2021 | 1048 | 0.060 |
Why?
| Virus Attachment | | | 16 | NaN |
Why?
| Salmeterol Xinafoate | 2 | 2018 | 41 | 0.060 |
Why?
| Macrophages | 2 | 2009 | 1459 | 0.060 |
Why?
| Exocrine Glands | 1 | 2004 | 5 | 0.060 |
Why?
| Basement Membrane | 1 | 2004 | 33 | 0.060 |
Why?
| Histamine H1 Antagonists | 1 | 2004 | 30 | 0.060 |
Why?
| Enterovirus | | | 78 | NaN |
Why?
| Leukotrienes | 1 | 2004 | 34 | 0.060 |
Why?
| Drug Administration Schedule | 1 | 2006 | 763 | 0.060 |
Why?
| Interleukin-12 Subunit p40 | 1 | 2003 | 9 | 0.050 |
Why?
| Administration, Sublingual | 2 | 2013 | 16 | 0.050 |
Why?
| Interleukin-13 | 2 | 2015 | 147 | 0.050 |
Why?
| Cells, Cultured | 3 | 2018 | 4058 | 0.050 |
Why?
| B-Lymphocytes | 1 | 2009 | 816 | 0.050 |
Why?
| Cell Count | 1 | 2004 | 317 | 0.050 |
Why?
| Disease Outbreaks | 1 | 2006 | 333 | 0.050 |
Why?
| Interleukin-12 | 1 | 2003 | 119 | 0.050 |
Why?
| Agriculture | 1 | 2003 | 91 | 0.050 |
Why?
| Administration, Topical | 1 | 2003 | 148 | 0.050 |
Why?
| Particulate Matter | | | 245 | NaN |
Why?
| Retrospective Studies | 2 | 2015 | 14669 | 0.050 |
Why?
| Cysteine | 1 | 2004 | 191 | 0.050 |
Why?
| Protein Subunits | 1 | 2003 | 230 | 0.050 |
Why?
| Middle Aged | 6 | 2016 | 31103 | 0.050 |
Why?
| Breast Feeding | 1 | 2006 | 424 | 0.050 |
Why?
| Interleukin-4 | 2 | 2015 | 214 | 0.050 |
Why?
| Epithelium | 1 | 2023 | 313 | 0.050 |
Why?
| Lymphocytes | 1 | 2004 | 369 | 0.050 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2021 | 73 | 0.050 |
Why?
| In Vitro Techniques | 1 | 2003 | 1063 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 1 | 2006 | 1969 | 0.050 |
Why?
| Interleukin-10 | 1 | 2003 | 299 | 0.050 |
Why?
| Nasal Provocation Tests | 1 | 2021 | 3 | 0.050 |
Why?
| Disease Susceptibility | 1 | 2003 | 339 | 0.050 |
Why?
| Practice Patterns, Physicians' | 1 | 2010 | 1287 | 0.050 |
Why?
| Inflammation | 3 | 2020 | 2705 | 0.050 |
Why?
| Th1 Cells | 1 | 2002 | 141 | 0.050 |
Why?
| Hydrocortisone | 1 | 2003 | 300 | 0.040 |
Why?
| Social Determinants of Health | | | 218 | NaN |
Why?
| T-Lymphocytes | 1 | 2009 | 1911 | 0.040 |
Why?
| Cytokines | 1 | 2008 | 2008 | 0.040 |
Why?
| Clinical Protocols | 1 | 2021 | 259 | 0.040 |
Why?
| Fungi | 1 | 2021 | 139 | 0.040 |
Why?
| Advisory Committees | 1 | 2021 | 231 | 0.040 |
Why?
| Breath Tests | 2 | 2012 | 94 | 0.040 |
Why?
| Anti-Inflammatory Agents | 1 | 2003 | 471 | 0.040 |
Why?
| A549 Cells | 1 | 2019 | 61 | 0.040 |
Why?
| Lymphocyte Activation | 1 | 2003 | 1095 | 0.040 |
Why?
| Common Cold | 1 | 2019 | 14 | 0.040 |
Why?
| Immunotherapy | 1 | 2004 | 581 | 0.040 |
Why?
| Lipids | 1 | 2023 | 614 | 0.040 |
Why?
| Diagnosis, Differential | 1 | 2003 | 1442 | 0.040 |
Why?
| Linear Models | 2 | 2013 | 823 | 0.040 |
Why?
| Vitamin D3 24-Hydroxylase | 1 | 2018 | 15 | 0.040 |
Why?
| Chicago | 1 | 2018 | 51 | 0.040 |
Why?
| Tacrolimus Binding Proteins | 1 | 2018 | 25 | 0.040 |
Why?
| Monitoring, Physiologic | 1 | 2020 | 268 | 0.040 |
Why?
| Analysis of Variance | 2 | 2015 | 1288 | 0.040 |
Why?
| Environmental Pollution | 1 | 2018 | 18 | 0.040 |
Why?
| Family | 1 | 2022 | 655 | 0.040 |
Why?
| Cell Death | 1 | 2019 | 342 | 0.040 |
Why?
| Maternal Health | 1 | 2018 | 45 | 0.040 |
Why?
| Interleukin-8 | 1 | 2018 | 262 | 0.030 |
Why?
| Caregivers | 1 | 2005 | 831 | 0.030 |
Why?
| Morbidity | 1 | 2018 | 303 | 0.030 |
Why?
| Receptors, Glucocorticoid | 1 | 2018 | 145 | 0.030 |
Why?
| Adrenergic beta-1 Receptor Agonists | 1 | 2016 | 5 | 0.030 |
Why?
| Metered Dose Inhalers | 1 | 2016 | 14 | 0.030 |
Why?
| Vital Capacity | 1 | 2017 | 284 | 0.030 |
Why?
| Folic Acid | 1 | 2018 | 182 | 0.030 |
Why?
| Evidence-Based Practice | 1 | 2018 | 215 | 0.030 |
Why?
| Gene Expression Regulation, Viral | 1 | 2017 | 91 | 0.030 |
Why?
| Child Health | 1 | 2018 | 145 | 0.030 |
Why?
| Signal Transduction | 2 | 2020 | 4863 | 0.030 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2008 | 644 | 0.030 |
Why?
| Models, Biological | 1 | 2003 | 1707 | 0.030 |
Why?
| Delayed-Action Preparations | 1 | 2016 | 178 | 0.030 |
Why?
| Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 6 | 0.030 |
Why?
| Bacteria | 1 | 2022 | 813 | 0.030 |
Why?
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 27 | 0.030 |
Why?
| Patient Participation | 1 | 2018 | 403 | 0.030 |
Why?
| Plant Proteins | 1 | 2014 | 92 | 0.030 |
Why?
| Respiratory Mucosa | 1 | 2017 | 313 | 0.030 |
Why?
| Cross Reactions | 1 | 2014 | 130 | 0.030 |
Why?
| Receptors, Immunologic | 1 | 2015 | 214 | 0.030 |
Why?
| Medication Adherence | 1 | 2018 | 576 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2016 | 7074 | 0.030 |
Why?
| Community Health Services | 1 | 2015 | 229 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 484 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2016 | 1227 | 0.030 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 379 | 0.030 |
Why?
| Th2 Cells | 1 | 2014 | 170 | 0.030 |
Why?
| Models, Genetic | 1 | 2015 | 586 | 0.030 |
Why?
| Alleles | 1 | 2015 | 849 | 0.030 |
Why?
| Eggs | 1 | 2012 | 31 | 0.020 |
Why?
| Bronchi | 1 | 2014 | 253 | 0.020 |
Why?
| Pregnancy | 2 | 2018 | 6274 | 0.020 |
Why?
| Mexican Americans | 1 | 2013 | 111 | 0.020 |
Why?
| Milk | 1 | 2012 | 129 | 0.020 |
Why?
| Patient Acceptance of Health Care | 1 | 2018 | 776 | 0.020 |
Why?
| Odds Ratio | 1 | 2014 | 1025 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2021 | 2539 | 0.020 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2018 | 544 | 0.020 |
Why?
| Reproducibility of Results | 2 | 2009 | 3054 | 0.020 |
Why?
| Poverty Areas | 1 | 2011 | 37 | 0.020 |
Why?
| Evidence-Based Medicine | 1 | 2015 | 731 | 0.020 |
Why?
| Drug Utilization | 1 | 2012 | 170 | 0.020 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2017 | 1049 | 0.020 |
Why?
| Critical Care | 1 | 2015 | 550 | 0.020 |
Why?
| Aged | 3 | 2016 | 22113 | 0.020 |
Why?
| Quality Improvement | 1 | 2018 | 1113 | 0.020 |
Why?
| Administration, Oral | 1 | 2012 | 790 | 0.020 |
Why?
| Sputum | 1 | 2012 | 309 | 0.020 |
Why?
| Histamine Release | 1 | 2009 | 20 | 0.020 |
Why?
| Cyclopropanes | 1 | 2009 | 88 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2013 | 1507 | 0.020 |
Why?
| Cell Degranulation | 1 | 2009 | 41 | 0.020 |
Why?
| Receptors, IgE | 1 | 2009 | 44 | 0.020 |
Why?
| Risk | 1 | 2012 | 871 | 0.020 |
Why?
| Acetates | 1 | 2009 | 99 | 0.020 |
Why?
| Sulfides | 1 | 2009 | 94 | 0.020 |
Why?
| Pilot Projects | 1 | 2013 | 1567 | 0.020 |
Why?
| Quinolines | 1 | 2009 | 149 | 0.020 |
Why?
| Drug Therapy, Combination | 1 | 2011 | 1024 | 0.020 |
Why?
| Drug Resistance | 1 | 2008 | 168 | 0.020 |
Why?
| Sickness Impact Profile | 1 | 2007 | 54 | 0.020 |
Why?
| Health Surveys | 1 | 2009 | 488 | 0.020 |
Why?
| Respiratory Physiological Phenomena | 1 | 2006 | 30 | 0.020 |
Why?
| Dexamethasone | 1 | 2008 | 331 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 773 | 0.020 |
Why?
| Vulnerable Populations | 1 | 2007 | 155 | 0.020 |
Why?
| Growth | 1 | 2006 | 57 | 0.020 |
Why?
| Monocytes | 1 | 2008 | 554 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2009 | 1849 | 0.010 |
Why?
| Disease-Free Survival | 1 | 2006 | 658 | 0.010 |
Why?
| Cats | 1 | 2005 | 211 | 0.010 |
Why?
| Cotinine | 1 | 2005 | 76 | 0.010 |
Why?
| Algorithms | 1 | 2012 | 1632 | 0.010 |
Why?
| Dogs | 1 | 2005 | 377 | 0.010 |
Why?
| Regression Analysis | 1 | 2006 | 992 | 0.010 |
Why?
| Cell Line | 1 | 2009 | 2768 | 0.010 |
Why?
| Program Evaluation | 1 | 2007 | 880 | 0.010 |
Why?
| Home Care Services | 1 | 2005 | 246 | 0.010 |
Why?
| Rats | 1 | 2009 | 5244 | 0.010 |
Why?
| Body Mass Index | 1 | 2009 | 2246 | 0.010 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 1291 | 0.010 |
Why?
| Colorado | 1 | 2005 | 4471 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|